VTX3232

About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biotech focused on developing oral small molecule therapies for diseases with high unmet medical need, primarily through inhibition of the NLRP3 inflammasome, a master regulator of inflammation. The company achieved a significant validation milestone in early 2026 with the announcement of its acquisition by pharmaceutical giant Eli Lilly, highlighting the strategic value of its platform and pipeline. Ventyx's strategy centers on targeting broad inflammatory conditions with convenient oral agents, aiming to improve upon the efficacy and tolerability of current standard-of-care treatments, including injectable biologics.

Therapeutic Areas